Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.72 USD | +2.36% | +2.63% | +45.17% |
03-19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
03-15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Sales 2024 * | 5.67M 452M | Sales 2025 * | 22.22K 1.77M | Capitalization | 2.08B 166B |
---|---|---|---|---|---|
Net income 2024 * | -175M -13.96B | Net income 2025 * | -200M -15.95B | EV / Sales 2024 * | 314 x |
Net cash position 2024 * | 304M 24.26B | Net cash position 2025 * | 123M 9.81B | EV / Sales 2025 * | 88,156 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-10.6
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.64% |
1 day | +2.36% | ||
1 week | +2.63% | ||
Current month | +2.36% | ||
1 month | -13.71% | ||
3 months | +0.87% | ||
6 months | +101.89% | ||
Current year | +45.17% |
Managers | Title | Age | Since |
---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 30/11/15 |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 31/01/20 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 30/06/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 16/12/20 |
Carl Gordon
CHM | Chairman | 59 | 29/02/20 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 30/11/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 57.72 | +2.36% | 468,530 |
30/04/24 | 56.39 | -3.80% | 202,915 |
29/04/24 | 58.62 | +1.31% | 211,127 |
26/04/24 | 57.86 | +6.77% | 291,970 |
25/04/24 | 54.19 | -3.65% | 261,556 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.17% | 2.08B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- KROS Stock